Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?

Yekeduz E., UTKAN G., Kanesvaran R., ÜRÜN Y.

PROSTATE INTERNATIONAL, cilt.9, sa.1, ss.1-5, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 9 Sayı: 1
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.prnil.2020.03.002
  • Dergi Adı: PROSTATE INTERNATIONAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.1-5
  • Anahtar Kelimeler: Androgen Receptor Antagonists, Androgen-Resistant Prostatic Cancer, Prostatic Neoplasms, ENZALUTAMIDE, SURVIVAL, APALUTAMIDE, MECHANISMS
  • Ankara Üniversitesi Adresli: Evet

Özet

Prostate cancer (PCa) is the most common cancer in men. Androgen receptor axis plays a crucial role in the carcinogenesis of PCa. The mainstay treatment of prostate cancer is blockage of androgen receptor axis but in a vast majority of patient resistance to androgen deprivation therapy is inevitable. After using enzalutamide, the first new generation anti-androgen (AA), two new generation AA drugs were synthesized. New generation anti-androgen drugs are used especially in castration resistance prostate cancer. But recently, there are new publications regarding using new generation anti-androgens in castration sensitive prostate cancer patients. In this review, we will compare structure, mechanisms of effect and clinical outcomes in phase 3 trials of these new generation AA drugs. (C) 2020 Asian Pacific Prostate Society. Published by Elsevier B.V.